Skip to main content

Table 5 Results of cost-effectiveness analysis (BRL/ months of life gained)

From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Strategy Cost (R$) Incremental cost (R$) Effectiveness (MLG) Incremental effectiveness (MLG) ICER
(BRL/MLG)
XELOX 41,396.84   97.07   
XELOX + bevacizumab 89,230.41 47,833.57 99.32 2.25 21,231.43
  1. Abbreviations: ICER Incremental cost-effectiveness ratio, MLG months of life gained, XELOX Xeloda® and oxaliplatin; BRL Brazilian real